A new Canadian study finds COVID-19 protection from first doses varies widely between vaccine brands. In some cases, a single dose of AstraZeneca’s shot formed no antibodies at all. as Jamie Mauracher reports, The findings add urgency to Canada’s efforts to get second doses rolled out as fast as possible.
- Canada, Mexico imported AstraZeneca doses from facility not fully inspected: regulator
- Canadian study finds mRNA vaccines produce more COVID-19 antibodies than AstraZeneca